NCT00004014View on ClinicalTrials.gov

Liposomal Doxorubicin in Treating Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

January 31, 2000

Study Completion Date

November 30, 2001

Conditions
Prostate Cancer
Interventions
DRUG

pegylated liposomal doxorubicin hydrochloride

Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.

Trial Locations (1)

44106-5065

Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER